Persephone Biosciences Will Provide 50,000 Free Synbiotics
Families can soon access a seven-day supply of synbiotics through participating pediatricians across the country.
Updated on Oct. 2, 2026 in Children’s Health
Live Poll
Would you ask your pediatrician about starting an infant synbiotic supplement for your child?
Persephone Biosciences will provide 50,000 free doses of synbiotics to families in 2027 through its pediatric network. This initiative aims to increase access to products designed to address microbiome deficiencies in infants.
Why it matters
Approximately 90% of U.S. infants currently lack key beneficial microbes for optimal development, a gap linked to various modern factors. The program aims to support microbiome education and expand the use of synbiotics in pediatric care.
In the ARTEMIS trial, results of which were published in Pediatric Research in August 2026, researchers measured the impact of synbiotics on infant microbiome composition. These findings follow previous published research in Cell Host & Microbe and Communications Biology.
The players
Persephone Biosciences
A biotechnology firm focused on developing microbiome-based therapeutic products for pediatric health.
The details
Synbiotics combine probiotics and prebiotics to support the survival and implantation of beneficial microbes in the infant digestive tract. By delivering these doses through pediatric sites, the program seeks to address widespread microbial gaps identified in nearly all infants. Participating pediatricians act as the point of contact for families seeking to evaluate if these supplements are appropriate for their child's developmental needs.
Timeline
August 2026: Positive results from the ARTEMIS trial were published.
October 2, 2026: The company announced the expansion of its starter program.
October 2-6, 2026: The AAP 2026 conference was held in San Diego.
2027: The company plans to distribute the free doses to families.
End of 2027: Target date for expansion to several thousand sites.
Health Landscape
The program builds upon findings from the ARTEMIS trial to address pediatric microbiome health. This rollout directly applies clinical evidence to a real-world setting, marking a shift toward broader preventative microbial support for infants.
If you are concerned about your child’s digestive health or development, you may want to ask your pediatrician about the availability of the Healthcare Practitioner Starter Program. It is important to discuss any new supplement use with your doctor to determine if it is appropriate for your infant.
The takeaway
Many infants in the U.S. currently lack beneficial microbes that may support development. Parents should track their child's health milestones and consult a pediatrician regarding whether microbiome support is relevant for their specific situation.
Further reading
For more on the current understanding of infant development, visit the Children’s Health section.
Live Poll
Would you ask your pediatrician about starting an infant synbiotic supplement for your child?
